Facebook
Twitter
LinkedIn
ForwardLymphomas
In this session we will review current principles and data supporting the utilization of radiation therapy for patients with hematologic malignancies. We will explore current treatment paradigms as well as modern radiation treatment techniques that are utilized in this patient population. We will examine the indications for cellular therapies and how radiation therapy can serve as a therapeutic partner for the treatment of refractory disease.
Target Audience
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Identify the indications for consolidative radiation therapy for patients with early stage Hodgkin lymphoma and Diffuse large B-cell lymphoma.
- Identify targeted and cellular therapies used currently for patients with hematologic malignancies and how radiation therapy can serve as a therapeutic partner in several settings.
- Describe current treatment approaches for indolent B-cell lymphoma.
Faculty:
A list of all meeting faculty and Individual presenter disclosures can be found on the Schedule of Events page.
Planning Committee:
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee webpage.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.